ABSTRACT
Linezolid and daptomycin resistance among Enterococccus faecium (Efm) isolates, while rare, is a major challenge for clinicians who are often limited to broad-spectrum or combination antibiotic therapies for management. Combination therapy with a beta-lactam has been reported, but limited clinical evidence exists to support its use. We describe the clinical management of a prolonged Efm intraabdominal (IA) infection and subsequent bacteremia, along with observed multidrug resistance development and use of serial whole genome sequencing to better understand resistance mechanisms. Combination antimicrobial therapy with daptomycin (DAP) and ceftaroline (CPT) was used to treat the patient’s catheter-associated daptomycin-, linezolid-, vancomycin-resistant Efm (DLVRE) bloodstream infection. In vitro antimicrobial testing of this DLVRE revealed only minor synergy between daptomycin and ceftaroline; However, the patient’s bacteremia cleared following initiation of combination therapy in conjunction with catheter removal. Sequencing of the patient’s DLVRE revealed multiple genomic mutations which explain both linezolid and daptomycin resistance and the presence of a plasmid containing known resistance determinants for vancomycin. Daptomycin resistance was attributed to the presence of chromosomal mutations in liaS (Thr120Ala), liaR (Trp73Cys), and cls (Asp13Ile), while linezolid resistance was attributed to the presence of the G2576T variant allele in some of 23S rRNA gene copies. Sequential whole genome sequencing of two additional bacterial isolates from the same patient revealed protracted colonization with a single DLVRE clone and suggested the development of bacterial subpopulations. Pairing clinical isolate susceptibilities with whole genome sequencing should be encouraged in clinical practice to better inform antimicrobial management in cases of multidrug resistance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from the National Institutes of Health (NIH)/National Institute of General Medical Sciences (NIGMS) (T32 GM008152 awarded to N.B.P), an American Cancer Society (ACS) Clinician Scientist Development Grant (#134251-CSDG-20-053-01-MPC, awarded to K.E.R.B.), and a Northwestern University Emerging and Re-emerging Pathogen Program (EREPP) grant (awarded to K.E.R.B.). This work was also supported by the Northwestern Memorial Clinical Microbiology laboratory and the NUSeq Core Facility which is generously supported by the NCI CCSG P30 CA060553 award to the Robert H. Lurie Comprehensive Cancer Center.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research study (STU00214816) was submitted for review to the Northwestern University Institutional Review Board and, because of the retrospective nature of this work, was deemed research that does not involve human subjects. Further IRB review and approval was, therefore, not required. In good faith, the case report was discussed openly with the patient in question and the patient verbally consented to its publication.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Co-first authors
Data Availability
All data produced in the present study are contained in the manuscript. Genomic sequences are available at the accession numbers listed in the methods.
